NASDAQ:GLYC - GlycoMimetics Stock Price, Forecast & News

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

GlycoMimetics Inc (NASDAQ:GLYC) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.39) by $0.08. View GlycoMimetics' Earnings History.

GlycoMimetics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for GlycoMimetics.

6 analysts have issued 12-month target prices for GlycoMimetics' shares. Their forecasts range from $5.00 to $18.00. On average, they anticipate GlycoMimetics' share price to reach $9.25 in the next twelve months. This suggests a possible upside of 118.7% from the stock's current price. View Analyst Price Targets for GlycoMimetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.

News stories about GLYC stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GlycoMimetics earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for GlycoMimetics.

Some companies that are related to GlycoMimetics include DiaMedica Therapeutics (DMCAF), Retrophin (RTRX), Provention Bio (PRVB), Eagle Pharmaceuticals (EGRX), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Omeros (OMER), BioXcel Therapeutics (BTAI), Aprea Therapeutics (APRE), RAPT Therapeutics (RAPT), Emisphere Technologies (EMIS), TherapeuticsMD (TXMD) and Vectura Group (VEGPF).

Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), Agile Therapeutics (AGRX), Amarin (AMRN), Viking Therapeutics (VKTX), Fate Therapeutics (FATE), TG Therapeutics (TGTX), Vanda Pharmaceuticals (VNDA), Amicus Therapeutics (FOLD), Gilead Sciences (GILD) and Nabriva Therapeutics (NBRV).

GlycoMimetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include AXA (2.18%), State Street Corp (1.48%), Oxford Asset Management LLP (0.31%), Panagora Asset Management Inc. (0.27%), Bank of New York Mellon Corp (0.26%) and UBS Group AG (0.21%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.

GLYC stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Alambic Investment Management L.P., State Street Corp, Bank of New York Mellon Corp and Bank of America Corp DE. View Insider Buying and Selling for GlycoMimetics.

GLYC stock was acquired by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Panagora Asset Management Inc., Jacobs Levy Equity Management Inc., California Public Employees Retirement System, Virtus ETF Advisers LLC, UBS Group AG, AXA and AQR Capital Management LLC. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il and Daniel M Junius. View Insider Buying and Selling for GlycoMimetics.

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GLYC stock can currently be purchased for approximately $4.23.

GlycoMimetics has a market capitalization of $183.41 million. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.View Additional Information About GlycoMimetics.

The official website for GlycoMimetics is http://www.glycomimetics.com/.

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]